Behind The Data: Iterative Engineering And Optimization Strategies For Maximizing LNP-mediated Gene Editing In The Liver

Improving in vivo liver editing potency requires coordinated optimization across every component of the system. Tyler McCullough explains how ElevateBio combines drug substance design, guide RNA chemistry, proprietary lipid nanoparticle formulations, protein engineering, and preclinical validation in an iterative workflow. Results across nuclease, base, and reverse transcriptase editing demonstrate how parallel development tracks can produce shared learnings and progressively improve performance at lower doses. The presentation also follows this optimization strategy from mouse models into nonhuman primates, where robust editing and target protein reduction point to further opportunities for refinement.

By connecting multiple editing modalities and engineering capabilities in one system, ElevateBio offers partners a more direct path toward potent, tolerable, and development-ready editor candidates.